Diepenbeek, Belgium, Feb 17, 2025 — InnoSer International, a leading preclinical Contract Research Organization (CRO) specializing in innovative solutions for drug development, proudly announces the appointment of Kris Motmans as the new Chief Executive Officer. This leadership transition will extend across all InnoSer subsidiaries in The Netherlands and Belgium, marking a new chapter for continued growth and innovation for the company.  

The decision to transfer responsibilities follows Jan Bartels’ planned retirement at the end of 2024. Jan stayed with the company during the transition to support the leadership handover and ensure alignment with InnoSer’s long-term goals for growth and innovation. This transition reflects InnoSer’s commitment to global expansion and the broadening of its service portfolio, with the aim of better serving customers in more locations. InnoSer’s core values and commitment to flexibility remain unchanged, ensuring we continue to prioritize our clients’ needs as a key part of our business activities. 

Kris Motmans holds a PhD in Medical Sciences.  As a seasoned executive, he has been instrumental in driving growth and innovation at various biotech and life science companies with over 20 years of experience in the industry. Thanks to his expertise within the CRO industry and having worked in preclinical research for two decades, Kris joined the InnoSer executive team as Chief Business Officer in 2021 and oversaw huge growth in the company. With in-depth knowledge of the market and InnoSer’s service portfolio Kris is uniquely positioned to assume the role of CEO previously held by Jan Bartels.

“Leading InnoSer into its next chapter is a privilege. I am committed to building on the strong foundation laid by previous leadership, increasing our global presence, and enhancing our in-house capabilities to ensure we remain at the forefront of the preclinical CRO industry.” commented Kris Motmans. “Having worked so closely with the team for over 3 years, I am excited about what we can achieve together and look forward to overseeing this next phase of InnoSer’s growth.”

About InnoSer 

Founded in 2012, InnoSer is an innovative and dynamic CRO supporting the pre-clinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug development journey with well-characterized in vitro and in vivo disease models in addition to general drug development services, allowing to uncover valuable insights into the mode of action, pharmacokinetics, safety, and efficacy of investigational compounds. 

www.innoserlaboratories.com